Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis
Status:
Active, not recruiting
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
Phase 1 Single Centre, open-labeled Clinical Trial to Evaluate the Safety and Tolerability of
Topical Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal
Candidiasis.
Participants that meet all inclusion and exclusion criteria will be enrolled to receive open
label NORM 3 doses/day for three weeks.